Serum biomarkers for the non-invasive diagnosis of liver fibrosis: The importance of being validated

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 4, 2012, Pages 595-597

  Sebastiani, Giada ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; NITROGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UREA;

EDITORIAL; HUMAN; LIVER FIBROSIS; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE;

EID: 84860430120     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0850     Document Type: Editorial

References (19)

1. Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fi brosis: it is time for laboratory medicine. Clin Chem Lab Med 2011;49:13-32.
2. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
3. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
4. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49:1017-44.
5. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fi brosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75. (Pubitemid 32322537)
6. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fi brosis. Hepatology 2005;42:1373-81. (Pubitemid 43260040)
7. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fi brosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42. (Pubitemid 39575660)
8. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fi brosis: a cohort study. Gastroenterology 2004;127:1704-13. (Pubitemid 39575849)
9. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fi brosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73. (Pubitemid 41368177)
10. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fi brosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012;56:55-62.
11. Guechot J, Trocme C, Renversez J-C, Strurm N, Zarski J-P. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 2012;50:693-9.
12. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fi brosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-31. (Pubitemid 46210918)
13. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fi brosis in chronic hepatitis C. Gastroenterology 2005;128: 343-50. (Pubitemid 40439195)
14. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fi brosis. Hepatology 2011;53:325-35.
15. Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, et al. Comparison of 8 diagnostic algorithms for liver fi brosis in hepatitis C: new algorithms are more precise and entirely non-invasive. Hepatology Epub 2011 Sep 2. doi: 10.1002/hep.24654.
16. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fi brosis: an updated meta-analysis. Hepatology 2011;53:726-36.
17. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fi brosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008;15: 212-8. (Pubitemid 351143742)
18. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fi brosis in chronic hepatitis C. Hepatology 2009;49: 1821-7
19. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fi brosis: does it take two to tango ? Gut 2010;59:861-6.